According to Pulse Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.7623. At the end of 2022 the company had a P/E ratio of -1.57.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.57 | -75.66% |
2021 | -6.47 | -41.72% |
2020 | -11.1 | 87.86% |
2019 | -5.91 | 13.41% |
2018 | -5.21 | -62.26% |
2017 | -13.8 | 66.47% |
2016 | -8.29 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | -35.3 | 176.60% | ๐ณ๐ฑ Netherlands |
![]() | -0.9720 | -92.38% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.